| # | Side effect | Count |
|---|---|---|
| 0 | GENERAL PHYSICAL HEALTH DETERIORATION | 6684 |
| 1 | ILL-DEFINED DISORDER | 3641 |
| 2 | DEATH | 1321 |
| 3 | DISEASE PROGRESSION | 360 |
| 4 | MALIGNANT NEOPLASM PROGRESSION | 343 |
| 5 | PROSTATIC SPECIFIC ANTIGEN INCREASED | 287 |
| 6 | LABORATORY TEST ABNORMAL | 266 |
| 7 | FATIGUE | 238 |
| 8 | ANAEMIA | 204 |
| 9 | PLATELET COUNT DECREASED | 168 |
| # | Side effect | Count | Frequency |
|---|---|---|---|
| 0 | HORMONE-DEPENDENT PROSTATE CANCER | 10 | 0.1429 |
| 1 | HORMONE-REFRACTORY PROSTATE CANCER | 167 | 0.1406 |
| 2 | ILL-DEFINED DISORDER | 3641 | 0.0599 |
| 3 | GENERAL PHYSICAL HEALTH DETERIORATION | 6684 | 0.0577 |
| 4 | METASTASES TO NERVOUS SYSTEM | 9 | 0.0489 |
| 5 | PROSTATIC SPECIFIC ANTIGEN DECREASED | 15 | 0.0397 |
| 6 | PROSTATE CANCER METASTATIC | 84 | 0.0251 |
| 7 | PROSTATIC SPECIFIC ANTIGEN ABNORMAL | 24 | 0.0231 |
| 8 | PROSTATIC SPECIFIC ANTIGEN INCREASED | 287 | 0.0208 |
| 9 | BLOOD CHROMOGRANIN A INCREASED | 9 | 0.0196 |